Skip Nav Destination
Issues
15 July 2005
-
Cover Image
Cover Image
- PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Editorial
The Biology Behind
Human Cancer Biology
Imaging, Diagnosis, Prognosis
In vivo Evaluation of 177Lu- and 67/64Cu-Labeled Recombinant Fragments of Antibody chCE7 for Radioimmunotherapy and PET Imaging of L1-CAM-Positive Tumors
Jürgen Grünberg; Ilse Novak-Hofer; Michael Honer; Kurt Zimmermann; Karin Knogler; Peter Bläuenstein; Simon Ametamey; Helmut R. Maecke; P. August Schubiger
Prognostic Significance of O6-Methylguanine-DNA Methyltransferase Determined by Promoter Hypermethylation and Immunohistochemical Expression in Anaplastic Gliomas
Marta Brell; Avelina Tortosa; Eugenia Verger; Juan Miguel Gil; Nuria Viñolas; Salvador Villá; Juan José Acebes; Lluis Caral; Teresa Pujol; Isidro Ferrer; Teresa Ribalta; Francesc Graus
Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype
Sunil R. Lakhani; Jorge S. Reis-Filho; Laura Fulford; Frederique Penault-Llorca; Marc van der Vijver; Suzanne Parry; Timothy Bishop; Javier Benitez; Carmen Rivas; Yves-Jean Bignon; Jenny Chang-Claude; Ute Hamann; Cees J. Cornelisse; Peter Devilee; Matthias W. Beckmann; Carolin Nestle-Krämling; Peter A. Daly; Neva Haites; Jenny Varley; Fiona Lalloo; Gareth Evans; Christine Maugard; Hanne Meijers-Heijboer; Jan G.M. Klijn; Edith Olah; Barry A. Gusterson; Silvana Pilotti; Paolo Radice; Siegfried Scherneck; Hagay Sobol; Jocelyne Jacquemier; Teresa Wagner; Julian Peto; Michael R. Stratton; Lesley McGuffog; Douglas F. Easton; the Breast Cancer Linkage Consortium
Cancer Therapy: Clinical
Thermal Dose Is Related to Duration of Local Control in Canine Sarcomas Treated with Thermoradiotherapy
Donald E. Thrall; Susan M. LaRue; Daohai Yu; Thaddeus Samulski; Linda Sanders; Beth Case; Gary Rosner; Chieko Azuma; Jeannie Poulson; Amy F. Pruitt; Wilma Stanley; Marlene L. Hauck; Laurel Williams; Paul Hess; Mark W. Dewhirst
Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab
Ola Lindén; Cecilia Hindorf; Eva Cavallin-Ståhl; William A. Wegener; David M. Goldenberg; Heather Horne; Tomas Ohlsson; Lars Stenberg; Sven-Erik Strand; Jan Tennvall
Cancer Therapy: Preclinical
Detection of Spontaneous CD4+ T-Cell Responses in Melanoma Patients against a Tyrosinase-Related Protein-2–Derived Epitope Identified in HLA-DRB1*0301 Transgenic Mice
Annette Paschen; Mingxia Song; Wolfram Osen; Xuan Duc Nguyen; Jan Mueller-Berghaus; Daniela Fink; Nadine Daniel; Mariel Donzeau; Wolfgang Nagel; Harald Kropshofer; Dirk Schadendorf
Detection of Human Papillomavirus (HPV) 16-Specific CD4+ T-cell Immunity in Patients with Persistent HPV16-Induced Vulvar Intraepithelial Neoplasia in Relation to Clinical Impact of Imiquimod Treatment
Mariëtte I.E. van Poelgeest; Manon van Seters; Marc van Beurden; Kitty M.C. Kwappenberg; Claudia Heijmans-Antonissen; Jan W. Drijfhout; Cornelis J.M. Melief; Gemma G. Kenter; Theo J.M. Helmerhorst; Rienk Offringa; Sjoerd H. van der Burg
CHIR-258: A Potent Inhibitor of FLT3 Kinase in Experimental Tumor Xenograft Models of Human Acute Myelogenous Leukemia
Daniel E. Lopes de Menezes; Jing Peng; Evelyn N. Garrett; Sharianne G. Louie; Sang H. Lee; Marion Wiesmann; Yan Tang; Lee Shephard; Cheryl Goldbeck; Yoko Oei; Helen Ye; Sharon L. Aukerman; Carla Heise
Letters to the Editor
Correction
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.